ABILITY PHARMACEUTICALS
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.
ABILITY PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.abilitypharma.com
Total Employee:
1+
Status:
Active
Contact:
+34 935 86 89 77
Email Addresses:
[email protected]
Total Funding:
19.26 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Font Awesome Apache Euro IPv6 Google Apps For Business
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Investors List
SciClone Pharmaceuticals
SciClone Pharmaceuticals investment in Corporate Round - Ability Pharmaceuticals
U.S. Food and Drug Administration
U.S. Food and Drug Administration investment in Grant - Ability Pharmaceuticals
Horizon 2020
Horizon 2020 investment in Grant - Ability Pharmaceuticals
European Innovation Council
European Innovation Council investment in Grant - Ability Pharmaceuticals
Inveready
Inveready investment in Venture Round - Ability Pharmaceuticals
Everis Group
Everis Group investment in Venture Round - Ability Pharmaceuticals
Capital Cell
Capital Cell investment in Venture Round - Ability Pharmaceuticals
Capital Cell
Capital Cell investment in Equity Crowdfunding - Ability Pharmaceuticals
Inveready
Inveready investment in Venture Round - Ability Pharmaceuticals
Official Site Inspections
http://www.abilitypharma.com
- Host name: hosting.twentic.com
- IP address: 178.33.116.190
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "Ability Pharmaceuticals"
The Company - Ability Pharma
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs"See details»
Management Team - Ability Pharma
Jul 30, 2024 Marc obtained his degree in Medicine and Surgery at the University of Barcelona in 1993. He started his medical activities as a volunteer at the refugee’s camps of the former YuSee details»
Ability Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number +34 935 86 89 77; ... a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the …See details»
AbilityPharma - LinkedIn
AbilityPharma receives World Health Organization approval for its ABTL0812 anticancer drug to be named #IBRILATAZAR. ... AbilityPharma's is currently conducting, with ABTL0812, the most advanced ...See details»
Ability Pharma Company Profile 2024: Valuation, …
Information on valuation, funding, acquisitions, investors, and executives for Ability Pharma. Use the PitchBook Platform to explore the full profile.See details»
Ability Pharmaceuticals - ASEBIO
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and …See details»
AbilityPharma Company Profile - Office Locations, Competitors
AbilityPharma has 5 employees across 2 locations. See insights on AbilityPharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Ability Pharma (fka AB Therapeutics) | VentureRadar
AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class causing autophagy molecules through binding to the nuclear receptors PPARa/?. It represents …See details»
AGC Pharma Chemicals and AbilityPharma work together to …
BARCELONA, 16th July 2024.-AGC Pharma Chemicals, an international Contract Development and Manufacturing Organization (CDMO) company based in Spain (Barcelona, Malgrat de …See details»
Ability Pharma - Products, Competitors, Financials, Employees ...
In March 2024, Catalan biopharmaceutical company AbilityPharma has obtained a €7m ($7.65m) investment to advance its Phase IIb clinical trial of ABTL0812, an autophagy inducer aimed at …See details»
Ability Pharmaceuticals SL - Drug pipelines, Patents ... - Patsnap
May 1, 2024 AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer. ... The …See details»
Ability Pharmaceuticals, SA | BIO-Europe Spring - Informa Connect
AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated …See details»
CSR - Ability Pharma
Jul 16, 2024 Ability Pharmaceuticals is an innovative and responsible company regarding the relationship with our stakeholders, suppliers, partners, institutions, employees, the …See details»
AbilityPharma - Biotech Careers
AbilityPharma is a clinical-stage biopharmaceutical company focused on developing fully differentiated oral targeted anticancer compounds that produce autophagy-mediated …See details»
Ability Pharma (company) | Nordic 9
Ability Pharma (company). AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class causing autophagy molecules through binding to the nuclear …See details»
AbilityPharma Announces € 7 Million Financing Round to Advance ...
Mar 11, 2024 AbilityPharma is completing a Phase 2b clinical trial with ABTL0812 in metastatic pancreatic cancer (all 140 patients recruited) with the aim of demonstrating greater efficacy …See details»
Pipeline - Ability Pharma
Jul 16, 2024 AbilityPharma has investigated the antiproliferative activity in a series of compounds, in in vitro models with several tumor cell lines. The mechanism causing the …See details»
Press Release - Ability Pharma
Dec 14, 2022 This is the key finding from the Phase 1/2 ENDOLUNG clinical trial, which was recently published in the prestigious scientific journal BMC Cancer. The trial evaluated the …See details»
AbilityPharma receives WHO approval for its ABTL0812 anticancer …
Aug 1, 2024 ABTL0812 has been given the International Non-proprietary Designation (INN) ibrilatazar on the recommended list of INNs issued by the World Health Organization (WHO)See details»